Search people, articles, bills, and more
This bill addresses a significant gap in the existing "Right to Try" law. While "Right to Try" allows terminally ill patients to access experimental drugs, it hasn't clearly covered investigational drugs that are classified as "Schedule I" substances, which are currently deemed to have no accepted medical use and a high potential for abuse. This classification severely restricts their availability, even for patients with no other hope.
If this bill becomes law, it would create a specific legal pathway for doctors to provide certain experimental Schedule I drugs to qualifying patients under the Right to Try framework. This means patients facing life-threatening conditions, for whom all other treatments have failed, might gain access to a broader range of experimental treatments, including those involving substances like certain psychedelics or cannabis-derived compounds that some believe hold therapeutic potential. Without this bill, access to these specific types of experimental drugs under Right to Try would likely remain severely limited, leaving fewer options for desperately ill patients.
No reactions yet. Be the first to weigh in.
This bill addresses a significant gap in the existing "Right to Try" law. While "Right to Try" allows terminally ill patients to access experimental drugs, it hasn't clearly covered investigational drugs that are classified as "Schedule I" substances, which are currently deemed to have no accepted medical use and a high potential for abuse. This classification severely restricts their availability, even for patients with no other hope.
If this bill becomes law, it would create a specific legal pathway for doctors to provide certain experimental Schedule I drugs to qualifying patients under the Right to Try framework. This means patients facing life-threatening conditions, for whom all other treatments have failed, might gain access to a broader range of experimental treatments, including those involving substances like certain psychedelics or cannabis-derived compounds that some believe hold therapeutic potential. Without this bill, access to these specific types of experimental drugs under Right to Try would likely remain severely limited, leaving fewer options for desperately ill patients.
An AI model extracted this from the bill’s official record and can make mistakes. Check the official text ↗ (opens in new tab)